Physician profile
Bruce Devon Ball
NPI 1912909599
$13,559.27
in general payments reported to CMS, 2019-2025
39 companies · $2,904 in 2025
The $2,904 reported for 2025 was more than what 75% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $1,316 · 2021: $2,774 · 2022: $1,613 · 2023: $1,587 · 2024: $1,930 · 2025: $2,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,300 · Consulting Fee: $71.47 · Education: $49.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,300.26 |
| Consulting Fee | $71.47 |
| Education | $49.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,296.68 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genentech USA, INC. | $1,772.48 | 2019-2025 | Xolair |
| Csl Behring | $1,433.57 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $1,277.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,237.01 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $833.01 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $701.88 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $649.93 | 2020-2025 | Cuvitru, Hyqvia, Glassia |
| Regeneron Healthcare Solutions, INC. | $454.80 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $373.39 | 2019-2025 | |
| Alk-Abello, INC | $339.05 | 2019-2022 | |
| Grifols USA, LLC | $284.79 | 2019-2025 | Xembify |
| Pharming Healthcare, INC. | $259.57 | 2020-2025 | Ruconest |
| Amgen INC. | $223.50 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $188.66 | 2020-2023 | Airduo Digihaler |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.